Table 2.
Multivariate analysis for PFS and relapse for patients undergoing 10/10-matched unrelated donor HCT for NHL.
| Variable | Hazard ratio | 95% confidence intervals | p-value |
|---|---|---|---|
| Progression free survival | |||
| KIR genotype | 0.0075 | ||
| KIR A/A | 1.0 | ||
| KIR B/x | 0.71 | 0.55–0.91 | |
| Disease status | 0.002 | ||
| Chemo sensitive | 1.0 | 0.87–2.83 | |
| Chemo resistant | 1.41 | 0.84–2.35 | |
| Complete Remission | 0.74 | 0.43–1.27 | |
| Lymphoma subset | 0.014 | ||
| Follicular lymphoma | 1.0 | ||
| Diffuse large B cell | 1.68 | 1.14–2.48 | |
| Mantle cell lymphoma | 1.61 | 1.12–2.3 | |
| T cell lymphoma +other | 1.62 | 1.16–2.3 | |
| Interval from Dx to HCT | 0.013 | ||
| ≤ 1.5 year | 1.0 | ||
| >1.5 year | 0.73 | 0.56–0.94 | |
| Relapse rate | |||
| KIR genotype | 0.018 | ||
| KIR A/A | 1.0 | ||
| KIR B/x | 0.63 | 0.43–0.92 | |
| Disease status | 0.039 | ||
| Chemo sensitive | 1.0 | ||
| Chemo resistant | 1.08 | 0.53–2.2 | |
| Complete remission | 0.51 | 0.24–1.09 | |
| T cell depletion in vivo | 0.0037 | ||
| No | 1.0 | ||
| Yes | 1.75 | 1.20–2.55 | |
| Interval from Dx to HCT | |||
| ≤ 1.5 year | 1.0 | 0.0003 | |
| >1.5 year | 0.49 | 0.33–0.72 | |